SEC Form 10-K filed by Eightco Holdings Inc.

Revenues Increased to $7.6 Million; Net Loss of $1.2 Million Easton, PA, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Eightco Holdings Inc. (NASDAQ:OCTO) ("Eightco" or the "Company") today announced financial results for the three and six months ended June 30, 2025. Second Quarter 2025 Financial Highlights Revenues of $7.6 million, compared to $5.3 million in the prior year quarter.Gross profit of $1.2 million, compared to $1.3 million in the prior year quarter.Operating loss of $1.2 million, compared to $0.9 million in the prior year quarter.Net loss of $1.2 million, or ($0.38) per share, compared to net income of $4.4 million, or $2.15 per diluted share, in the prior year quarter. First Six Mon

Quarter Driven by Focus on Deploying Capital into the Refurbished Apple Products Business and Prioritizing Financial Stability for Long-Term Growth First quarter 2025 revenue growth of 25% to $9.9mn compared to $8.0mn for the prior year quarter, due to focus on refurbished apple products salesFirst quarter 2025 operating loss of $1.4mn, a reduction of 55% compared to an operating loss of $3.2mn for the prior year quarter, due to lower SG&A and absence of restructuring and severance expenses in the first quarter of 2025 Easton, PA, May 16, 2025 (GLOBE NEWSWIRE) -- Eightco Holdings Inc. (NASDAQ:OCTO) (the "Company" or "Eightco") today announced financial results for the three months ended

Easton, PA, April 28, 2025 (GLOBE NEWSWIRE) -- Eightco Holdings Inc. (NASDAQ:OCTO) (the "Company" or "Eightco") today announced the appointment of Nicola Caiano to its Board of Directors. Mr. Caiano brings over three decades of expertise in financial strategy, capital markets, and investment management, further strengthening Eightco's strategic vision and growth trajectory. Mr. Caiano currently serves as Chief Financial Officer at Cytometric Therapeutics, where he leads capital formation strategies to fund clinical trials for groundbreaking cancer therapies. He is also the Founding Partner of Olea Management LLC, where he advises family offices and early-stage companies across diverse ind

3 - Eightco Holdings Inc. (0001892492) (Issuer)

4 - Eightco Holdings Inc. (0001892492) (Issuer)

3 - Eightco Holdings Inc. (0001892492) (Issuer)

Easton, PA, April 28, 2025 (GLOBE NEWSWIRE) -- Eightco Holdings Inc. (NASDAQ:OCTO) (the "Company" or "Eightco") today announced the appointment of Nicola Caiano to its Board of Directors. Mr. Caiano brings over three decades of expertise in financial strategy, capital markets, and investment management, further strengthening Eightco's strategic vision and growth trajectory. Mr. Caiano currently serves as Chief Financial Officer at Cytometric Therapeutics, where he leads capital formation strategies to fund clinical trials for groundbreaking cancer therapies. He is also the Founding Partner of Olea Management LLC, where he advises family offices and early-stage companies across diverse ind

SC 13G/A - Eightco Holdings Inc. (0001892492) (Subject)